Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. - Wikidata - awgldk - TriplyDB

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

http://www.wikidata.org/entity/Q33633402

about

Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers Salpingectomy as a means to reduce ovarian cancer risk Management of Menopausal Symptoms.Identification et prise en charge des femmes ayant des antécédents familiaux de cancer du sein: Guide pratique à l’intention des médecins Identification and management of women with a family history of breast cancer: Practical guide for clinicians Personalized assessment and management of women at risk for breast cancer in North America Genetic testing for RAD51C mutations: in the clinic and community Inherited Mutations in Women With Ovarian Carcinoma Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario.An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.BRCA1 founder mutations compared to ovarian cancer in Belarus.BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers Inherited predisposition to breast cancer among African American women.Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families.Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru.The fallopian tube: from back stage to center stage.Prophylactic oophorectomy for hereditary small cell carcinoma of the ovary, hypercalcemic type Low grade serious carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a "low-grade serous tubal intra-epithelial carcinoma" (STIC) on risk reducing surgery.Ten modifiers of BRCA1 penetrance validated in a Norwegian series Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.Single-port versus conventional multiport access prophylactic laparoscopic bilateral salpingo-oophorectomy in high-risk patients for ovarian cancer: a comparison of surgical outcomes Is it time to offer BRCA1 and BRCA2 testing to all Jewish women?Ovarian cancer survival by tumor dominance, a surrogate for site of origin.DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.The Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA Carriers Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.SEOM clinical guidelines in Hereditary Breast and ovarian cancer.Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.Reproductive Endocrinologists' Utilization of Genetic Counselors for Oncofertility and Preimplantation Genetic Diagnosis (PGD) Treatment of BRCA1/2 Mutation Carriers.Genetic characterization of early onset ovarian carcinoma.Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

P2860

Q26747279-36EF0D40-BA99-4664-A580-5B09F568DA74 Q27003935-B1B37EB2-EB9A-49B6-A225-DD2D03BD3760 Q27011949-5715528E-24AA-4FA1-833C-8B08896EDF40 Q27318357-8C15F7D2-0531-46B3-BD4D-EE02AA48A71B Q28077316-7999C6FB-6FAD-4E36-914D-D6FB2700D374 Q28077578-480AF28D-2022-44CF-892C-F0A7F96D1EF5 Q28083876-10528519-57B8-4FED-ADAD-657F4F92F9DB Q28253197-93A0B6EA-31D4-4FDF-8162-870F4EEC76EA Q30353433-1FF878C6-2B5D-4F10-A9CA-EBC08434E793 Q30370475-BB659187-32F0-47F4-B16B-9E99AC9A9E2A Q33563963-E875A01F-2659-4462-8451-1B86AEDE83F9 Q33669849-79509F9E-E17F-4F76-A212-FEA1AE2E8E0D Q33901361-B7DB6889-2140-4210-9DBA-B1D582FD2B0E Q34185187-C10FA72B-9B68-42DF-9C96-FF4785430FEC Q34283643-9C385F65-BEDB-4BDE-811B-48B883901893 Q34475484-6468B909-CABE-49F4-AB65-6C3C03CF04E8 Q34983596-CA921230-5867-47C8-9049-C1461ACC60B6 Q34988799-D7182661-778D-4254-8D36-707A779CAE81 Q34996647-86CE77D0-2485-4770-A8DC-B1CBA658CF2E Q35007651-8EE9A5E7-4423-43A1-94C6-ABE25B9C10F2 Q35179515-2DCAA17B-06F0-4197-B36B-782F639BF4AC Q35217775-CB12F599-F90F-45EE-8F9F-448A06DF1177 Q35562911-DA45A370-11DB-44CE-AD0D-FFC333FADC6D Q35642043-F40D5029-9787-448E-A94E-9DFADBD3E448 Q35642063-918A7D5B-FF71-4624-BAE5-40C53672F0F9 Q35686538-5039F1F1-4D2F-444E-8C83-D803B1089D26 Q35690548-795BA393-E73C-41C3-A56D-A3CAEDE1BC98 Q35749439-305DC841-8B36-478E-A9DF-98DCB9D385B1 Q35799433-D7B0E1FF-BC57-4B08-924F-38F44915C911 Q35934272-FEBB1ABC-BC81-4D60-90AC-1F9D5302214C Q36032691-BFC4EF58-4FE6-4F41-A3AD-C59A58B7A1B7 Q36203244-D9158F0A-BC7F-4766-8F9B-C71D139D0B18 Q36218446-186B14D0-BBBB-4675-9851-273DF49EAE32 Q36261447-5DB5D647-7EC3-4826-A4F5-D9527705F6BE Q36313479-2A8DD118-AE67-48D3-A2E6-A8E71FBB04E8 Q36400244-0F68B73A-6739-4519-B46B-4B4C7CE8878E Q36634141-C5B2481C-BBC8-47A6-8EB5-D564F94A28CC Q36901615-E36F7FD1-830D-4977-9EED-85BC37BD8092 Q36908973-30E8F8EA-33C7-4886-91D2-657078E94BC5 Q36915151-33824BFB-DCEE-408C-B3CF-7B8341F62BEE

P2860

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

http://www.wikidata.org/entity/Q33633402

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Impact of oophorectomy on canc ...... ith a BRCA1 or BRCA2 mutation.

@ast

Impact of oophorectomy on canc ...... ith a BRCA1 or BRCA2 mutation.

@en

type

label

Impact of oophorectomy on canc ...... ith a BRCA1 or BRCA2 mutation.

@ast

Impact of oophorectomy on canc ...... ith a BRCA1 or BRCA2 mutation.

@en

prefLabel

Impact of oophorectomy on canc ...... ith a BRCA1 or BRCA2 mutation.

@ast

Impact of oophorectomy on canc ...... ith a BRCA1 or BRCA2 mutation.

@en

P1433

Q33633402-AFF08DD3-DDDA-4302-AC46-A2DE4CB2CD6A

P1476

Q33633402-5AADB1C2-CEFB-4789-B5FE-6F5466BFC02B

P2093

Q33633402-1672F127-C26F-4325-BD4C-EB56C0DC542B

Q33633402-1AED4FDA-6547-412E-AB7F-656541D0E6FA

Q33633402-1B307DB8-7E0F-431C-BE7F-ABDB45197A7A

Q33633402-2E05ADE5-DDE7-464F-839F-A9B4D1E52380

Q33633402-30C2E0EC-DADF-485E-8A26-73AD14FC22DB

Q33633402-32C7580F-EF0D-4F3B-B293-61A239931E7F

Q33633402-3A533BCF-7ADA-4DB1-B88D-3EA51C24F840

Q33633402-3EC24041-0107-4C87-8DBC-A30FFE8752AE

Q33633402-4C62D8ED-3121-4B69-9F75-6E7EB3880F7F

Q33633402-8EB9FACE-A0EE-492D-BF8A-9263A98022DC

P2860

Q33633402-119DE71E-518E-4721-9448-C81D7CC3B7D9

Q33633402-2F6B6F1A-B8B6-45BB-BC43-D99880A5D71F

Q33633402-47F3F25D-9956-4969-914A-9FE906150362

Q33633402-48C74D1C-BE01-4D06-AB79-0AC7B60D901B

Q33633402-5F13FFD9-C6E3-4FDA-8913-7DE904B093DC

Q33633402-67D6E104-BB8B-4F0E-9A30-C8FC9F90738A

Q33633402-6A75FDB7-D201-41EF-A69C-9B0A7AA430D6

Q33633402-A5A3A4A6-C6C1-4A49-9A29-0CDC6139055E

Q33633402-AE075262-0D4F-4E03-A2E7-4061F2FA1DAD

Q33633402-B29D7300-E928-4551-BF4A-00D9052DBF11

P304

Q33633402-8BDDB7DF-02E3-46B3-99BF-346AC009F104

P31

Q33633402-0028B114-C542-4581-BEE6-BAB63B3A7CC4

P356

Q33633402-CF9D1ED9-0454-4C44-98E6-2101954629EB

P407

Q33633402-A34E06DF-12E9-483B-A261-B2A5D0721AE0

P433

Q33633402-9ED1AF59-A4AE-483A-8E90-DCAD42CF0DE3

P478

Q33633402-23A281BD-7F19-4C87-84AB-5431077F37E3

P50

Q33633402-03690E01-3FCD-4223-8F86-B1E6F38B8EBE

Q33633402-43A825A9-9ED5-47B8-AE16-DA74F317A420

Q33633402-49158A47-C99D-40AE-9D25-52616435B87E

Q33633402-A0B25960-F2A7-4EC4-BE04-A9131759C74B

Q33633402-E2A83B94-AB2E-4AD0-ABFB-522C816424BF

P577

Q33633402-01827C16-5AB6-4667-AE9A-65AB3275496B

P5875

Q33633402-79FB0852-E18B-426C-B333-5B972B6BE6E4

P698

Q33633402-5F25FAB7-3BD6-4C82-AF36-C2F5298060F5

P932

Q33633402-DA68DAF2-4DDB-45B0-9EA8-56D0DB1F00DD

P356

JCO.2013.53.2820

P1433

Journal of Clinical Oncology

P1476

Impact of oophorectomy on canc ...... ith a BRCA1 or BRCA2 mutation.

@en

P2093

Amy P M Finch

http://www.w3.org/2001/XMLSchema#string

Andrea Eisen

http://www.w3.org/2001/XMLSchema#string

Barry Rosen

http://www.w3.org/2001/XMLSchema#string

Beth Karlan

http://www.w3.org/2001/XMLSchema#string

Charmaine Kim-Sing

http://www.w3.org/2001/XMLSchema#string

Christian F Singer

http://www.w3.org/2001/XMLSchema#string

Henry T Lynch

http://www.w3.org/2001/XMLSchema#string

Islay Thompson

http://www.w3.org/2001/XMLSchema#string

Joan Murphy

http://www.w3.org/2001/XMLSchema#string

Kelly A Metcalfe

http://www.w3.org/2001/XMLSchema#string

P2860

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.

Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.

Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

P304

1547-1553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.53.2820

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

William D Foulkes

Cezary Cybulski

Steven A. Narod

Susan L Neuhausen

P577

2014-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260379261

http://www.w3.org/2001/XMLSchema#string

P698

24567435

http://www.w3.org/2001/XMLSchema#string

P932

4026578

http://www.w3.org/2001/XMLSchema#string